A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma
Public ClinicalTrials.gov record NCT06149286. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Open Label, Randomized Study to Compare the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Combination With Lenalidomide Versus Rituximab in Combination With Lenalidomide in Relapsed/Refractory Participants With Follicular Lymphoma and Marginal Zone Lymphoma (OLYMPIA-5)
Study identification
- NCT ID
- NCT06149286
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Enrollment
- 470 participants
Conditions and interventions
Conditions
Interventions
- Lenalidomide Drug
- Odronextamab Drug
- Rituximab Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 27, 2023
- Primary completion
- Jan 22, 2029
- Completion
- Jan 22, 2029
- Last update posted
- May 5, 2026
2023 – 2029
United States locations
- U.S. sites
- 8
- U.S. states
- 7
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| David Geffen School of Medicine at UCLA | Los Angeles | California | 90095 | Recruiting |
| Boca Raton Clinical Research (BRCR) Global | Plantation | Florida | 33322 | Recruiting |
| Indiana University and Comprehensive Cancer Center | Indianapolis | Indiana | 46202 | Recruiting |
| Hattiesburg Clinic | Hattiesburg | Mississippi | 39401 | Recruiting |
| Dartmouth Cancer Center | Lebanon | New Hampshire | 03756 | Recruiting |
| Stony Brook University Hospital | Stony Brook | New York | 11794 | Recruiting |
| Clinical Research Alliance Inc | Westbury | New York | 11590 | Withdrawn |
| Prohealth Care Inc | Waukesha | Wisconsin | 53188 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 161 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06149286, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 5, 2026 · Synced May 10, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06149286 live on ClinicalTrials.gov.